Increases in antimicrobial resistance globally are likely to hit African countries the hardest. Strengthening the local infrastructure aimed at combating infection is the only way to counter it.

Delandistrogene moxeparvovec received FDA approval after a negative trial, which highlights the many complexities and challenges of drug development in this setting.

Biological aging clocks are flawed concepts in understanding disease.

Pharmaceutical companies are investing in therapies that target proteins for degradation, with trials ongoing for cancer, autoimmune diseases and neurological disorders.

The primary report of the EMBARK phase 3 trial, testing the AAV-based gene therapy delandistrogene moxeparvovec in Duchenne muscular dystrophy, did not meet its primary endpoint of improvement in NSAA mobility scores compared to placebo. Secondary endpoints show that the therapy was safe and associated with improvements in micro-dystrophin expression and in individual mobility scores.

Using data from a cohort of patients (n = 346) with lung adenocarcinoma and from multiple independent cohorts, DNA methylation signatures were evaluated to build and validate an accurate model predicting the development of brain metastasis.

Individuals with Parkinson’s disease treated with prasinezumab demonstrated slower motor progression over 4 years compared with an external comparator cohort derived from the Parkinson’s Progression Markers Initiative observational study.

Using ethnically and geographically diverse metagenomic data, the authors identify microbiota alterations associated with inflammatory bowel disease (IBD). They discover universal IBD-associated bacteria, which serve as the basis for a multibacteria biomarker panel that could support a noninvasive tool for IBD diagnosis.

In participants from a randomized controlled trial, doxy-PEP use over 6 months minimally affected the gut microbiome’s taxonomic composition but increased the abundance and active expression of tetracycline antibiotic resistance genes.

In the phase 3 EVER-132-002 trial, patients with HR⁺HER2⁻ metastatic breast cancer from Asia were treated with the Trop-2-directed antibody–drug conjugate sacituzumab govitecan or chemotherapy, and those receiving sacituzumab govitecan experienced prolonged progression-free survival compared with patients treated with chemotherapy.

Research and interventions where children may disclose violence require effective, resourced and context-specific safeguarding response plans.

Increases in antimicrobial resistance globally are likely to hit African countries the hardest. Strengthening the local infrastructure aimed at combating infection is the only way to counter it.

Biological aging clocks are flawed concepts in understanding disease.

Pharmaceutical companies are investing in therapies that target proteins for degradation, with trials ongoing for cancer, autoimmune diseases and neurological disorders.